Rare haematologic and neurologic drug reactions from immune checkpoint inhibition in a responding patient with metastatic anorectal mucosal melanoma
Immune checkpoint inhibitors (ICIs) blocking engagement with the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) or the programmed death 1 (PD-1) receptors have emerged to dramatically improve the treatment outcome of various advanced cancer types. In melanoma, the combination of nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) has demonstrated significantly improved long-term survival [1].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Sarah Qaiyumi, Wolfram Klapper, Axel Hauschild, Michael Weichenthal Tags: Letter to the Editor Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Drugs & Pharmacology | Melanoma | Neurology | Skin Cancer | Yervoy